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A chronic wound is burdensome for patients, the healthcare system and wider society. These wounds can last for a long time, often in excess of a
year. The prevalence of chronic wounds was estimated to be growing at the rate of 12% per annum in a study looking at 2000 patients in The Health
Improvement Network database 1.
With this increasing prevalence, the costs of wound care are also rising, an estimated £1.94 billion spent on Leg Ulcers in 2012/3 and in 2014/5 £1
billion spent on Diabetic Foot Ulcers in the United Kingdom 2,3. Standard care for wounds varies depending on the type, however they include items
such as dressings, debridement, infection control, compression and offloading, delivered by a multidisciplinary team of health care providers 4,5.
Background
To examine the economic impact of topical interventions for chronic wounds and the variance associated with standard care.
The methodological quality of the studies that were included in this review was assessed by use of the CHEERS statement. Of a maximum available
18 points awarded by the checklist a range of scores between 10-15 were awarded, with a mean of 12.9.
The treatment in question was cost-effective or cost-saving in 14 of the 15 studies. The exception; Chuang et al6, evaluated a randomized controlled
trial of ultrasound therapy for hard‐to‐heal venous leg ulcers found no benefit and more expense associated with the ultrasound therapy.
In an environment of budget cuts and financial pressure on health care systems, cost-effective solutions to health care problems are desirable.
Cost-effective interventions for wound care are not necessarily those that are the cheapest at the point of use, the use of the least costly
interventions may not lead to the best possible healing outcomes for patients in terms of full closure, time to healing and risk of recurrence.
Improving healing outcomes would alleviate strain on the healthcare system, as long as the uncertainty surrounding evidence supporting new
treatments can be balanced with high quality clinical trials supported by accurate economic modelling.
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Objective
Methods Results
Conclusions
After initial screening of the 3422 titles and abstracts, 2585 were 
excluded for not being relevant to the research objective. The remaining 
817 texts were judged against the inclusion and exclusion criteria. Finally, 
15 texts were included as per the PRISMA flow chart. 
The studies predominantly examined VLU, with 10 studies focusing on 
these patients, 3 studies looked at DFU and one each for Chronic Wounds 
and Pressure Ulcers. 
Across the 15 studies, standard care (or good wound care) was used 10 
times, including where standard care was provided together with the 
study treatment.  
Seven studies were set in the UK, of these standard care was used in 3, 
reporting a cost of standard care for DFU outpatient and inpatients, 
£3330 and £4488 respectively. For VLU, a mean annual cost of £1385·51 
– £1795·30 per patient was reported.
A systematic review following the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines undertaken. 
Searches of: Science Direct, National Institute for Health and Clinical 
Excellence Evidence search, Medline (PubMed), Centre of Reviews and 
Dissemination (University of York), Cochrane Database and discussion 
with experts and manufacturers to identify additional literature. Two 
researchers performed data extraction, with a third consulted where 
there were disagreements. 
Economic endpoints: incremental cost-effectiveness ratio, cost-per 
Quality Adjusted Life Year and disease related resource use. 
A narrative synthesis of results and critical appraisal using the 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
statement were performed. 
Table 1: Inclusion /Exclusion criteria
Inclusion criteria
Population Chronic wounds
Interventions Topical dressings or applications
Outcomes Economic outcomes
Study design RCT with economic evaluation. Any economic study or modelling
Language English Language
Search dates After 1987
Exclusion criteria
Population Paediatrics, Acute wounds (including Burns, Trauma, Surgery)
Interventions Surgical. Novel non-surgical (including electrical stimulation,
hyperbaric treatment. Infection control measures. Debridement.
Bioengineered skin substitutes. Offloading
Outcomes Not meeting inclusion criteria
Study design In vitro studies, review or discussion articles
Language Non-English language (if the abstract was available in English and
enough data was available, this was included in the data
extraction).
Search dates Before 1987
Figure 1. PRISMA flow diagram
